RNAssist is attending the World Vaccine Congress

Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™!

We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, "TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines" will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.

RNAssist, in collaboration with CPI and funded by Innovate UK, has developed TheraPHIX™—a pioneering solution that keeps mRNA-LNP formulations stable at ambient temperatures, reducing the need for cold chain logistics and opening up new possibilities for global healthcare.

This innovation will enhance vaccine availability in remote and low-income regions, lowering costs and ensuring equitable access to life-saving treatments.

Be sure to follow us on LinkedIn for updates on TheraPHIX™ or contact us to learn more.

We look forward to seeing you at the Congress!